Cachexia

U.S. FDA allows phase 2 trial of treatment for cachexia in lung cancer patients to proceed

Published in Cancer Weekly, February 13th, 2007

Vicus Therapeutics, LLC, an oncology-focused, clinical-stage biopharmaceutical company, announced that the Division of Oncology Drug Products of the U.S. Food and Drug Administration (FDA) has determined that it is safe to proceed with the phase 2 trial of VT-122.

The compound will be tested for the treatment of cachexia in weight losing subjects with Stage IV, non-small cell lung cancer (NSCLC). The phase 2 clinical trial will be conducted in the United States and India, and is expected to be completed in Q3 2007.

This multicenter, randomized, open-label controlled study will assess the safety and efficacy of VT-122 regimen administered to weight...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-02-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry